ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

This is an open-label, uncontrolled phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma. The study consists of 2 phases, a Dose Escalation Phase and an Expansion Phase. Nivolumab will be administered, consistent with the US prescribing information, as a 30-minute IV infusion on Days 1 and 15 of each 28-Day cycle. ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day cycle (i.e., every 8 weeks).

Inclusion criteria

• Men or women, Age ≥18 years
• Patients with ECOG performance status 0 or 1
• Patients with histologically confirmed diagnosis of HCC not amenable to curative surgery or local therapy
• Patients with documented objective radiographic progression during or after local therapy or after treatment with sorafenib or lenvatinib or intolerance to or refusal to receive either agent
• Patients with at least one prior systemic therapy for HCC
• Patients eligible to be treated with nivolumab
• Patients with measurable disease based on RECIST v1.1
• Patients with Child-Pugh class A liver score within 7 days of first study dose
• Patients with no history of hepatic encephalopathy
• Patients with no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible)
• Patients with HBV infection must have received antiviral therapy for at least 12 weeks and HBV viral load must be documented to be <100 IU/mL within 7 days of first study dose
• Patients with no active co-infection with HBV and HCV or HBV and HDV
• Patients with no active drug or alcohol abuse

Exclusion criteria

• Patients with tyrosine kinase inhibitor treatment within 2 weeks of first study dose
• Patients with esophageal or gastric variceal bleeding within the past 6 months
• Patients with portal vein invasion at the main portal (Vp4) or the inferior vena cava or cardiac involvement of HCC based on imaging
• Patients with previous solid organ or hematologic transplantation
• Patients with active autoimmune disease requiring systemic treatment in the past 2 years
• Patients with diagnosis of immunodeficiency or receiving systemic steroid therapy or other immunosuppressive therapy within 7 days before first study dose
• Patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose
• Patients with minor surgery to liver or another site within 1 week before first study dose